RxDoctor Payments Data

Katherine Lee

Dermatology · Laguna Hills, CANPI 1265693691

Payments from drug & device makers

$122,247in general payments, 2019–2025

Across 838 payments — averaging $145.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$58K
  • Botanix SB Inc$16K
  • Barco, Inc.$16K
  • Pfizer$6K
  • AbbVie$6K
  • Sanofi US Services Inc.$5K
  • plus $15K from 33 others
$21,478in research payments, 2019–2025

Across 12 payments — averaging $1789.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$13K
  • Eli Lilly$8K

What the payments were for

  • Consulting fees$14,84126%
  • Speaking & faculty fees$25,55645%
  • Travel & lodging$1,8203%
  • Food & beverage$13,63624%
  • Education$5641%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$122,247 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$162,483
Medicare patients
251
Services billed
3,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab26$95,171
Dupixent SyringeDupilumab11$42,694
OpzeluraRuxolitinib Phosphate11$22,663
EnstilarCalcipotriene/Betamethasone11$14,744
Ketoconazole152$3,722
Tacrolimus30$3,217
Clobetasol Propionate63$2,722
Metronidazole40$1,682
Doxycycline Hyclate38$1,615
Fluorouracil31$1,538
Clindamycin Phosphate23$1,388
Fluocinonide28$809
Betamethasone Dipropionate16$736
Ciclopirox24$732
Mupirocin48$564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$795$22,66311 claims
LEO Pharma Inc.Enstilar$618$14,74411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,875 dermatology providers in California.

Other dermatology in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →